Nerve growth factor (NGF) is a target-derived polypeptide that acts through its receptor, trkA, to serve as a trophic factor for neurons in the peripheral nervous system (PNS) and central nervous system (CNS). The NGF signal must be transported retrogradely in axons from the target of neurons to their cell bodies. The molecular and cellular basis of retrograde signalling is unknown. Preliminary data suggests that activated trkA receptors in intracellular vesicles could be the signalling entity. We propose to test the hypothesis: that intracellular signalling of activated trkA in vesicles provides the means by which the NGF signal is carried from axon tips to the cell body.
Four Specific Aims are proposed. In the first, we will define membrane trafficking of NGF receptors in PC12 cells. Biotinylation will be used to define the rates for constitutive and ligand-induced internalization of trkA and p75. Using trkA mutants, we will characterize the relationship between signal transduction and endocytosis. We will isolate coated vesicles and determine whether trkA is internalized via a clathrin-coated pit mechanism. In the second Aim, we will characterize activated trkA in intracellular vesicles. We will define conditions for producing vesicles in which trkA tyrosine phosphorylation and trkA kinase activity are optimized. The signalling proteins associated with activated trkA in vesicles will also be defined.
In Aim 3 we will test the ability of activated trkA-containing vesicles to signal in vitro and in vivo. In vitro studies will examine phosphorylation of signalling intermediates (e.g. PLC-gamma, SHC) and activation of kinase activities (e.g. ERK1). In in vivo studies we will microinject naive PC12 cells and assess induction of immediate early gene expression, neurite outgrowth and cellular hypertrophy.
In Aim 4 we will use the Campenot compartmented culture system to examine retrograde signalling in sympathetic neurons. Using biochemical and morphological criteria, we will characterize retrograde transport of NGF, the NGF signal and activated trkA to establish whether or not they are identical in their kinetics and susceptibility to colcimid block. The proposed studies are expected to provide important new insights into how it is that neurons and their targets communicate. Through elucidation of signalling molecules and mechanisms, our studies may make possible novel opportunities for understanding and treating disorders of the nervous system, including Alzheimer's disease.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Research Project (R01)
Project #
5R01NS024054-11
Application #
2445743
Study Section
Neurology C Study Section (NEUC)
Program Officer
Leblanc, Gabrielle G
Project Start
1986-07-01
Project End
1998-06-30
Budget Start
1997-07-01
Budget End
1998-06-30
Support Year
11
Fiscal Year
1997
Total Cost
Indirect Cost
Name
University of California San Francisco
Department
Neurology
Type
Schools of Medicine
DUNS #
073133571
City
San Francisco
State
CA
Country
United States
Zip Code
94143
Belichenko, Pavel V; Madani, Rime; Rey-Bellet, Lorianne et al. (2016) An Anti-?-Amyloid Vaccine for Treating Cognitive Deficits in a Mouse Model of Down Syndrome. PLoS One 11:e0152471
Nosheny, R L; Belichenko, P V; Busse, B L et al. (2015) Increased cortical synaptic activation of TrkB and downstream signaling markers in a mouse model of Down Syndrome. Neurobiol Dis 77:173-90
Ruparelia, Aarti; Pearn, Matthew L; Mobley, William C (2013) Aging and intellectual disability: insights from mouse models of Down syndrome. Dev Disabil Res Rev 18:43-50
Rodrigues, Elizabeth M; Weissmiller, April M; Goldstein, Lawrence S B (2012) Enhanced ýý-secretase processing alters APP axonal transport and leads to axonal defects. Hum Mol Genet 21:4587-601
Ruparelia, Aarti; Pearn, Matthew L; Mobley, William C (2012) Cognitive and pharmacological insights from the Ts65Dn mouse model of Down syndrome. Curr Opin Neurobiol 22:880-6
Sung, Kijung; Maloney, Michael T; Yang, Jingkun et al. (2011) A novel method for producing mono-biotinylated, biologically active neurotrophic factors: an essential reagent for single molecule study of axonal transport. J Neurosci Methods 200:121-8
Belichenko, Nadia P; Belichenko, Pavel V; Kleschevnikov, Alexander M et al. (2009) The ""Down syndrome critical region"" is sufficient in the mouse model to confer behavioral, neurophysiological, and synaptic phenotypes characteristic of Down syndrome. J Neurosci 29:5938-48
Wu, Chengbiao; Cui, Bianxiao; He, Lingmin et al. (2009) The coming of age of axonal neurotrophin signaling endosomes. J Proteomics 72:46-55
Salehi, A; Faizi, M; Colas, D et al. (2009) Restoration of norepinephrine-modulated contextual memory in a mouse model of Down syndrome. Sci Transl Med 1:7ra17
Chial, Heidi J; Wu, Ruping; Ustach, Carolyn V et al. (2008) Membrane targeting by APPL1 and APPL2: dynamic scaffolds that oligomerize and bind phosphoinositides. Traffic 9:215-29

Showing the most recent 10 out of 61 publications